



**Dr. Kevin Kobylinski**

Principal Investigator

Armed Forces Research Institute of Medical Sciences, Thailand

Dr. Kevin Kobylinski is a medical entomologist focused on developing and characterizing novel vector control interventions. His primary research interest has been characterizing the utility of ivermectin mass drug administration (MDA) for malaria parasite transmission suppression. Ivermectin is a broad spectrum anthelmintic used to treat numerous neglected tropical diseases in humans. His work in Senegal demonstrated that ivermectin MDAs can kill wild *Anopheles gambiae* and reduce sporozoite prevalence in the mosquito population. He has also assessed ivermectin susceptibility of important malaria vectors in Southeast Asia and South America. In addition to the direct killing effect, he has shown that ivermectin has sublethal effects including inhibition of mosquito re-feeding and sporontocidal effect against *Plasmodium falciparum* in *An. gambiae* and *P. vivax* in *An. dirus*, *An. minimus*, and *An. darlingi*. He has initiated clinical trials to assess the safety, tolerability, pharmacokinetics, and mosquito-lethal efficacy of ivermectin with dihydroartemisinin-piperaquine and primaquine. Field studies of ivermectin MDA are being initiated in Southeast Asia to assess capabilities to suppress *P. vivax* and *P. falciparum* transmission in the region.